EFFICACY AND DISCONTINUATION RATE OF IBRUTINIB IN TREATMENT NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH TP53 ABNORMALITIES. A REAL‐LIFE CAMPUS CLL STUDY

Autor:	A. Visentin, F. R. Mauro, F. Cibien, C. Vitale, G. Reda, A. Fresa, S. Ciolli, D. Pietrasanta, M. Marchetti, R. Murru, M. Gentile, G. M. Rigolin, F. M. Quaglia, L. Scarfò, P. Sportoletti, S. Pravato, L. Romano Gargarella, M. Facco, F. Piazza, M. Coscia, L. Laurenti, S. Molica, G. Pizzolo, R. Foà, A. Cuneo, L. Trentim
Rok vydání:	2021
Předmět:	Oncology Cancer Research medicine.medical_specialty business.industry Chronic lymphocytic leukemia Hematology General Medicine medicine.disease Discontinuation Therapy naive chemistry.chemical_compound chemistry Ibrutinib Internal medicine medicine business
Zdroj:	Hematological Oncology. 39
ISSN:	1099-1069 0278-0232
DOI:	10.1002/hon.46_2880
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::6fabce6397760ec72a7b27eb7ff4dfbd https://doi.org/10.1002/hon.46_2880 Zobrazit plný text záznamu Plný text